Non-exclusive licensing agreement between Agilent and Callida should boost commercialisation of DNA microarray technology
Agilent Technologies and Callida Genomics have announced a non-exclusive licensing agreement that grants Callida both up-front fees and potential running royalties, and gives Agilent access to Callida's early microarray patent portfolio for commercial use in the field of non-universal DNA microarrays. "This license enhances our extensive microarray patent portfolio and furthers our ability to bring new DNA microarray solutions to the life sciences community," said Barney Saunders, vice president and general manager of Agilent's Bioresearch Solutions business.
"This agreement secures access to an important set of patents derived from Dr Radoje Drmanac, currently CSO at Callida, who conducted pioneering work in the early development of microarrays." "We are pleased that Agilent is able to utilis our DNA microarray patents," said George Rathman, interim president, chairman and CEO of Callida Genomics.
"This agreement fits nicely with our licensing strategy for non-universal probes, further validating the strength of our patent portfolio and providing us with future royalty revenue opportunities."
